Neuroprotective or Neurohype? Unpacking GLP-1 Agonists in Brain Health and Weight Loss
Bibliographic record
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially developed for type 2 diabetes management, but emerging research suggests they may have significant neuroprotective properties (Du et al., 2022). These agents have been shown to reduce neuroinflammation, enhance synaptic plasticity, and mitigate oxidative stress, which are key contributors to neurodegenerative diseases such as Alzheimer’s and Parkinson’s (Cummings et al., 2025). Additionally, GLP-1 RAs appear to improve cognitive function, even in non-diabetic individuals, raising interest in their potential as therapeutic interventions for neurodegenerative and psychiatric disorders (Vadini et al., 2020). Recent studies highlight the ability of GLP-1 RAs to reduce amyloid-beta accumulation and tau pathology, hallmark features of Alzheimer’s disease, while also exerting dopaminergic protective effects relevant to Parkinson’s disease (Meissner et al., 2024). Given the rising popularity of GLP-1 RAs like Ozempic for weight loss, questions remain about their broader cognitive effects, long-term safety, and whether their neuroprotective benefits are independent of glucose metabolism. Further research is needed to determine their full potential in brain health, optimal dosing strategies, and possible risks associated with chronic use. This review explores current findings on the neurological effects of GLP-1 RAs and their implications for future treatment strategies in neurodegenerative diseases.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".